GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis
Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with significant cardiovascular (CV) benefits in patients with type 2 diabetes mellitus (DM). However, the efficacy and safety among different agents across diverse patient populations remain inadequately defined. Purpose We conducted a systematic review, along with pairwise and network meta-analysis, to assess the safety and […]
Trump’s MRI remains a mystery
Presented by the Coalition to Strengthen America’s Healthcare {beacon} Health Care PRESENTED BY COALITION TO STRENGTHEN AMERICA’S HEALTHCARE The Big Story Trump’s MRI remains a mystery A week after President Trump’s off-the-cuff remark that he had an MRI scan performed, we still don’t know why. And it will likely stay that way. © Photo credit Trump’s disclosure raised fresh questions about the secrecy surrounding […]
Do GLP-1 drugs cause cancer? New review says no, may even protect
A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and increased cancer risk, countering early safety concerns. Instead, evidence suggests possible protective effects for certain cancers, supported by metabolic and immune-modulating mechanisms.
Metsera in the middle of Novo, Pfizer bidding war
Pfizer Inc. upped its original $7.3 billion September offer to buy Metsera Inc., but the obesity specialist maintained that a now-improved unsolicited bid by semaglutide developer Novo Nordisk A/S is superior.
Is there really an Ozempic baby boom?
These medications may be influencing fertility in ways scientists are only beginning to understand. When the GLP-1 medications were first approved for weight loss, “I got pregnant on Ozempic” headlines quickly followed. People spoke about sudden unintended pregnancy, and “Ozempic babies” entered the lexicon. Could a medication meant to combat diabetes and shrink waistlines also […]
GLP-1 drugs calm inflammation beyond diabetes and weight loss
This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent mechanisms. It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.
Madrigal CEO welcomes MASH competition from Novo as demand climbs higher for Rezdiffra
Madrigal Pharmaceuticals CEO Bill Sibold doesn’t seem worried about sharing the MASH market with Novo Nordisk’s blockbuster GLP-1 drug. In an interview with Endpoints News on Tuesday, Sibold touted the tolerability of Madrigal’s approved MASH …
White House nears deal to lower prices for weight loss drugs Wegovy and Zepbound
The Trump administration is preparing to announce a deal this week with Eli Lilly and Novo Nordisk to lower the price of their weight loss drugs, a person familiar with the plan said.
White House nears deal to lower obesity drug prices for Medicare coverage
The GLP-1 drugs, produced by Novo Nordisk and Eli Lilly, have been credited with helping weight-loss, preventing diabetes and other positive effects.
After the FDA crackdown, here’s how some companies are still selling GLP-1s
Microdosing isn’t just about mushrooms any more. While taking tiny non-psychedelic doses of hallucinogens was once the health craze du jour, small, sub-clinical doses of weight loss drugs have taken over the term “microdosing” in 2025. Little research has been done on the efficacy of GLP-1 drugs like Ozempic when prescribed in smaller doses, but […]